Chiome Bioscience Inc. (4583) AI Stock Analysis

• Market Cap: ¥8.01B
• Dividend Yield: N/A
• Average Volume (3M): 521.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: 25.28%
• EPS Growth: 39.15%
• Country: JP
• Employees: 47
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.82
• Shares Outstanding: 68,453,800
• 10 Day Avg. Volume: 796,530
• 30 Day Avg. Volume: 521,303
• PEG Ratio: 0.53
• Price to Book (P/B): 8.15
• Price to Sales (P/S): 20.05
• P/FCF Ratio: -15.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: ¥105.00 ▼(-0.94% Downside)

The score is primarily held back by persistent large losses and ongoing cash burn despite improved revenue growth and solid gross margins. Technicals also weaken the outlook, with price below major moving averages and a negative MACD. Valuation is only modestly supportive given the negative P/E and no dividend yield data.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful R&D monetization and potential for future profitability as the company scales its operations.

Gross Margins

Solid gross margins suggest that the company can potentially achieve profitability at the gross level, supporting long-term financial health.

Leverage

Low leverage provides financial flexibility and reduces risk, allowing the company to invest in R&D without excessive debt burden.

Negative Factors

Profitability

Persistent unprofitability indicates challenges in scaling operations and achieving sustainable margins, impacting long-term viability.

Cash Flow

Continued cash burn necessitates external funding, which may dilute equity and limit strategic flexibility until cash flow improves.

Sales Decline

Declining sales highlight challenges in commercializing products, potentially hindering revenue growth and market competitiveness.

Chiome Bioscience Inc. Business Overview & Revenue Model

Company Description

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development; and Human ADLib System, a chicken antibody gene converted to humanized antibodies. The company also provides protein expression and purification services; stable cell line generation services for recombinant protein and antibody production; and antibody generation services using the ADLib system or B cell cloning techniques. Its product pipeline comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer which is under phase 1 trial; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma which is under phase 1 trial; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and breast cancer (TNBC) which is under phase 1 trial. The company's product pipeline under preclinical study includes LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; BMAA, an anti-semphorin3a antibody for treating central, immune/ inflammatory diseases, neurological disorder, and ophthalmic diseases; PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, triple negative breast cancer; and PFKR, anti-CX3CR1 antibody for secondary progressive multiple sclerosis. It serves universities, research institutions, and pharmaceutical companies. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Chiome Bioscience Inc. generates revenue primarily through the development and commercialization of its therapeutic antibody candidates. The company earns money by licensing its proprietary ADLib system technology to other pharmaceutical companies, enabling them to discover and develop their own antibody products. Additionally, Chiome may receive milestone payments and royalties from partnerships and collaborations with other biotech and pharmaceutical firms. These partnerships often involve co-development agreements where Chiome contributes its expertise in antibody research and development. The company's revenue model is also supported by potential government grants and funding for its research endeavors.

Chiome Bioscience Inc. Financial Statement Overview

Summary

Chiome Bioscience Inc. shows revenue growth but struggles with profitability due to persistent negative net income and EBIT. The company has a strong equity position and low leverage but faces challenges with cash flow, indicating a need for improved operational efficiencies.

Income Statement

Chiome Bioscience Inc. shows a consistent increase in total revenue over recent years, with a noticeable revenue growth rate of 14.41% from 2023 to 2024. However, the company suffers from persistently negative net income and EBIT, leading to negative net profit margins and EBIT margins. This suggests the company is struggling to convert revenue into profit, a pressing concern for financial health.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 77.81% in 2024, indicating a solid foundation of stockholders' equity relative to total assets. The debt-to-equity ratio remains low at 0.15, highlighting minimal leverage risk. However, persistent losses and continued reliance on equity financing could pose future sustainability challenges.

Cash Flow

Chiome Bioscience Inc. exhibits stable operational cash outflows, with operating cash flow improving slightly from 2023 to 2024. However, the free cash flow remains negative, and the free cash flow to net income ratio indicates operational inefficiencies. These aspects highlight challenges in achieving positive cash flow without external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	768.88M	780.81M	682.46M	630.82M	712.93M	480.85M
Gross Profit	436.96M	432.85M	398.60M	348.86M	422.46M	245.27M
EBITDA	-985.87M	-1.01B	-1.21B	-1.24B	-1.46B	-1.29B
Net Income	-997.11M	-1.02B	-1.22B	-1.24B	-1.48B	-1.29B
Balance Sheet
Total Assets	1.96B	2.47B	1.75B	2.22B	2.34B	3.49B
Cash, Cash Equivalents and Short-Term Investments	1.47B	2.06B	1.33B	1.73B	1.79B	2.69B
Total Debt	260.50M	281.50M	291.00M	184.00M	183.00M	180.00M
Total Liabilities	443.39M	548.55M	593.73M	424.72M	446.39M	384.59M
Stockholders Equity	1.52B	1.92B	1.16B	1.79B	1.89B	3.11B
Cash Flow
Free Cash Flow	0.00	-1.00B	-1.07B	-1.19B	-1.13B	-1.36B
Operating Cash Flow	0.00	-1.00B	-1.07B	-1.19B	-1.13B	-1.36B
Investing Cash Flow	0.00	0.00	173.00K	0.00	-35.38M	-3.52M
Financing Cash Flow	0.00	1.74B	667.30M	1.13B	271.35M	1.94B

Chiome Bioscience Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 106.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4583, the sentiment is Neutral. The current price of 106 is below the 20-day moving average (MA) of 109.55, below the 50-day MA of 116.56, and below the 200-day MA of 133.97, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 56.41 is Neutral, neither overbought nor oversold. The STOCH value of 79.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4583.

Chiome Bioscience Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4584	55 Neutral	¥11.60B	36.06	―	―	83.60%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4588	50 Neutral	¥44.44B	-18.47	―	―	-9.04%	13.09%
2370	46 Neutral	¥8.47B	-6.22	―	―	5.44%	-2.17%
4583	45 Neutral	¥8.01B	-8.70	―	―	25.28%	39.15%
4893	43 Neutral	¥6.32B	-8.08	―	―	-12.01%	26.66%
4571	40 Underperform	¥10.80B	-13.65	-26.70%	―	172.39%	8.27%

Chiome Bioscience Inc. Corporate Events

Chiome Bioscience Reports Continued Losses Amidst Declining Sales

Chiome Bioscience Inc. reported its financial results for the nine months ending September 30, 2025, showing a decrease in net sales and continued losses. The company has not revised its financial forecasts, indicating ongoing challenges in its drug discovery and development business, while maintaining a focus on its drug discovery support services.